Literature DB >> 29684821

The direct cost of epilepsy in children: Evidence from the Medical Expenditure Panel Survey, 2003-2014.

Alain Lekoubou1, Kinfe G Bishu2, Bruce Ovbiagele3.   

Abstract

INTRODUCTION: Epilepsy is frequent in children and often requires complex healthcare interventions. There is a paucity of recent and detailed healthcare expenditures among children with epilepsy in the United States (US).
METHODS: Data on children (aged ≤17years) from the Medical Expenditure Panel Survey-Household Component (MEPS-HC) from 2003 to 2014 were analyzed. Unadjusted overall and specific cost components were compared between children with epilepsy and those without epilepsy. We used a two-part model with gamma distribution and log link for the estimation of independent incremental cost incurred by epilepsy in children. Unadjusted and adjusted mean expenditures and aggregate burden of epilepsy were estimated.
RESULTS: Out of 54,393,387 (weighted) US children, 457,873 (0.84%) had epilepsy. Children with epilepsy had nearly six times higher healthcare expenditure than those without epilepsy ($2024 [95% confidence interval (CI): 1917-2130] vs. $12,577 [95% CI: 7922-17,231]). Unadjusted inpatient expenditure for epilepsy ($4418 [95% CI: 1550-7285) was ten times higher than that for children without epilepsy, representing more than one-third of unadjusted total direct cost. The adjusted difference in medical expenditure between children with and those without epilepsy was $8317 (95% CI: 3701-13,363). The annual unadjusted aggregate cost of epilepsy in children was approximately $5.8 billion. The annual adjusted difference in cost of epilepsy between children with and those without epilepsy was $3.8 billion.
CONCLUSION: Unadjusted and adjusted medical expenditure among children with epilepsy is high. The high expenditure is essentially driven not only by inpatient expenditure but also by home healthcare, outpatient, and medication healthcare expenditures.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; Direct cost; Epilepsy; United States

Mesh:

Year:  2018        PMID: 29684821     DOI: 10.1016/j.yebeh.2018.03.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  3 in total

1.  Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice.

Authors:  Darshan Mehta; Matthew Davis; Andrew J Epstein; G Rhys Williams
Journal:  Clinicoecon Outcomes Res       Date:  2020-07-23

2.  Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective.

Authors:  Yani Hu; Haibin Dai
Journal:  Ann Transl Med       Date:  2022-03

3.  Expression of miR-155 in Serum Exosomes in Children with Epilepsy and Its Diagnostic Value.

Authors:  Ya Liu; Gang Yu; Yan-Yan Ding; Yong-Xia Zhang
Journal:  Dis Markers       Date:  2022-07-26       Impact factor: 3.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.